Beyond Building Blocks: Amino Acids in Therapeutic Design

Ayon NJ. Features, roles and chiral analyses of proteinogenic amino acids. AIMS Mol Sci. 2020;7(3):229. doi: 10.3934/molsci.2020011

Das K, Balaram H, Sanyal K. Amino acid chirality: stereospecific conversion and physiological implications. ACS Omega. 2024;9(5):5084. doi: 10.1021/acsomega.3c08305

Gu F, Thomas D, Newberry RW. Backbone nitrogen substitution restricts the conformation of glycine residues in β-turns. ChemComm. 2026;62(1):227-230. doi: 10.1039/d5cc06335c

Cava F, De Pedro MA, Lam H, Davis BM, Waldor MK. Distinct pathways for modification of the bacterial cell wall by non-canonical D-amino acids. EMBO J. 2011;30(16):3442. doi: 10.1038/emboj.2011.246

Kozlowski LP. IPC 2.0: prediction of isoelectric point and pKa dissociation constants. Nucleic Acids Res. 2021;49(W1):W285-W292. doi: 10.1093/nar/gkab295

Shao J, Kuiper BP, Thunnissen AMWH, et al. The role of tryptophan in π interactions in proteins: an experimental approach. J Am Chem Soc. 2022;144(30):13815-13822. doi: 10.1021/jacs.2c04986

McGaughey GB, Gagné M, Rappé AK. π-stacking interactions: alive and well in proteins. J. Biol. Chem. 1998;273(25):15458-15463. doi: 10.1074/jbc.273.25.15458.

Meyer EA, Castellano RK, Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed. 2003;42(11):1210-1250. doi: 10.1002/anie.200390319

Raum HN, Modig K, Akke M, Weininger U. Proton transfer kinetics in histidine side chains determined by pH-dependent multi-nuclear NMR relaxation. J Am Chem Soc. 2024;146(32):22284. doi: 10.1021/jacs.4c04647

Dombkowski AA, Sultana KZ, Craig DB. Protein disulfide engineering. FEBS Lett. 2014;588(2):206-212. doi: 10.1016/j.febslet.2013.11.024

Wang Y, Li Y, Chen J, Lai L. Modeling protein–ligand interactions for drug discovery in the era of deep learning. Chem Soc Rev. 2025;54(23):11141-11183. doi: 10.1039/d5cs00415b

Jorgensen WL. The many roles of computation in drug discovery. Science. 2004;303(5665):1813-1818. doi: 10.1126/science.1096361

Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384-13421. doi: 10.3390/molecules200713384

De Vivo M, Masetti M, Bottegoni G, Cavalli A. Role of molecular dynamics and related methods in drug discovery. J Med Chem. 2016;59(9):4035-4061. doi: 10.1021/acs.jmedchem.5b01684

Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432(7019):862-865. doi: 10.1038/nature03197

Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010;15(11-12):444-450. doi: 10.1016/j.drudis.2010.03.013

Kaserer T, Beck KR, Akram M, Odermatt A, Schuster D. Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases. Molecules. 2015;20(12):22799-22832. doi: 10.3390/molecules201219880

Giordano D, Biancaniello C, Argenio MA, Facchiano A. Drug design by pharmacophore and virtual screening approach. Pharmaceuticals. 2022;15(5):646. doi: 10.3390/ph15050646

De Boer D, Nguyen N, Mao J, Moore J, Sorin EJ. A comprehensive review of cholinesterase modeling and simulation. Biomolecules. 2021;11(4):580. doi: 10.3390/biom11040580

Sussman JL, Harel M, Frolow F, et al. Atomic Structure of Acetylcholinesterase from Torpedo californica: A Prototypic Acetylcholine-Binding Protein. Science. 1991;253(5022):872-879. doi:10.1126/science.1678899

Luque FJ, Muñoz-Torrero D. Acetylcholinesterase: a versatile template to coin potent modulators of multiple therapeutic targets. Acc Chem Res. 2024;57(4):450. doi: 10.1021/acs.accounts.3c00617

Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020;25(6):1375. doi: 10.3390/molecules25061375

Ou-Yang S sheng, Lu J yan, Kong X qian, Liang Z jie, Luo C, Jiang H. Computational drug discovery. Acta Pharmacol Sin. 2012;33(9):1131-1140. doi: 10.1038/aps.2012.109

Smith MC, Gestwicki JE. Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med. 2012;14:e16. doi:10.1017/erm.2012.10

Nada H, Choi Y, Kim S, Jeong KS, Meanwell NA, Lee K. New insights into protein–protein interaction modulators in drug discovery and therapeutic advance. Signal Transduct Target Ther. 2024;9(1):341. doi: 10.1038/s41392-024-02036-3

Zheng B, Wang X, Guo M, Tzeng CM. Therapeutic peptides: recent advances in discovery, synthesis, and clinical translation. Int J Mol Sci. 2025;26(11):5131. doi: 10.3390/ijms26115131

Khalily MP, Soydan M. Peptide‐based diagnostic and therapeutic agents: Where we are and where we are heading? Chem Biol Drug Des. 2023;101(3):772-793. doi: 10.1111/cbdd.14180

Jarosinski MA, Dhayalan B, Chen YS, Chatterjee D, Varas N, Weiss MA. Structural principles of insulin formulation and analog design: A century of innovation. Mol Metab. 2021;52:101325. doi: 10.1016/j.molmet.2021.101325

Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care. 2021;9(1):e002301. doi: 10.1136/bmjdrc-2021-002301

Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. doi: 10.1021/acs.jmedchem.5b00726

Apostolopoulos V, Bojarska J, Chai TT, et al. A global review on short peptides: frontiers and perspectives. Molecules. 2021;26(2):430. doi: 10.3390/molecules26020430

Mehrdadi S. Lipid-based nanoparticles as oral drug delivery systems: Overcoming poor gastrointestinal absorption and enhancing bioavailability of peptide and protein therapeutics. Adv Pharm Bull. 2023;14(1):48. doi: 10.34172/apb.2024.016

Adhikari A, Bhattarai BR, Aryal A, et al. Reprogramming natural proteins using unnatural amino acids. RSC Adv. 2021;11(60):38126-38145. doi: 10.1039/d1ra07028b

Han J, Konno H, Sato T, Soloshonok VA, Izawa K. Tailor-made amino acids in the design of small-molecule blockbuster drugs. Eur J Med Chem. 2021;220:113448. doi: 10.1016/j.ejmech.2021.113448

Lovering F. Escape from Flatland 2: complexity and promiscuity. Medchemcomm. 2013;4(3):515-519. doi: 10.1039/C2MD20347B

Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009;52(21):6752-6756. doi: 10.1021/jm901241e.

Liu J, Han J, Izawa K, et al. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur J Med Chem. 2020;208:112736. doi:10.1016/j.ejmech.2020.112736

Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943-4960. doi: 10.1128/AAC.00296-11

Guy S, Hickey K, Maclean R. Review of the current ıssues surrounding monitoring of the direct thrombin inhibitor argatroban in the laboratory. Int J Lab Hematol. 2026;48(4):737-746. doi:10.1111/ijlh.70103

Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975;195(3):453-464. doi:10.1016/S0022-3565(25)30363-0

Larden DW, Cheung HTA. Synthesis of N-α-aminoacyl derivatives of melphalan for potential use in drug targeting. Tetrahedron Lett. 1996;37(42):7581-7582. doi: 10.1016/0040-4039(96)01665-6

Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119(6):492-502. doi: 10.7326/0003-4819-119-6-199309150-00009

Peisach J, Blumberg WE. A mechanism for the action of penicillamine in the treatment of Wilson’s disease. Mol Pharmacol. 1969;5(2):200-209.

Wuis EW, Dirks MJM, Termond EFS, Vree TB, Van der Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol. 1989;37(2):181-184. doi: 10.1007/BF00558228

Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41(6):889-926. doi: 10.2165/00003495-199141060-00007

Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov. 2008;7(10):801-802. doi: 10.1038/nrd2694

Raja A, LaBonte J, Lebbos J, Kirkpatrick P. Daptomycin. Nat Rev Drug Discov. 2003;2(12):943-944. doi: 10.1038/nrd1258